Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy. PMID: 32150489 DOI: Item in Clipboard Full-text links Cite Abstract Purpose: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report (...) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other

2020 EvidenceUpdates

2. Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer

Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer Drug Approval Package: TABRECTA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TABRECTA Company: Novartis Pharmaceuticals Corporation Application Number: 213591 Approval Date: 05/06/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

3. Archimedes for biopsy of suspected lung cancer

navigation systems. Archimedes for biopsy of suspected lung cancer (MIB211) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 10Current care pathway Current care pathway People with known or suspected lung cancer should be offered a contrast-enhanced chest CT scan to diagnosis and stage the disease. They should also be offered endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for biopsy (...) of paratracheal and peri-bronchial intra- parenchymal lung lesions. When taking samples, the healthcare professional should ensure they are adequate (without unacceptable risk to the person) to permit pathological diagnosis, including tumour subtyping and assessment of predictive markers. The following publications have been identified as relevant to this care pathway: • NICE's guideline on lung cancer: diagnosis and management • NICE's quality standard on lung cancer in adults • NICE's interventional

2020 National Institute for Health and Clinical Excellence - Advice

4. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Jul 1;38(19):2187-2196. doi: 10.1200/JCO.19.02674. Epub 2020 May 14. Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

2020 EvidenceUpdates

5. Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. (Abstract)

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced (...) of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment.Among patients

2020 NEJM

6. eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations

eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment (...) cancer (NSCLC) who have not progressed following chemoradiotherapy whose tumours express programmed death-ligand 1 (PD-L1) on ≥1% of tumour cells, although the latter was a post hoc subgroup analysis. The recommendation is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab, commenced 1–42 days post chemoradiotherapy, improved both progression-free survival [PFS; median PFS 16.8 versus 5.6 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.42–0.65, P <0.0001

2020 European Society for Medical Oncology

7. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 212 2 Information about lorlatinib Information about lorlatinib Marketing authorisation indication Marketing authorisation indication 2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non- small cell lung cancer (NSCLC) whose disease has progressed after: • alectinib or ceritinib as the first ALK (...) that there was a significant unmet need for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), even though 4 ALK tyrosine kinase inhibitor (TKI) treatments are available. The committee noted that neither crizotinib nor ceritinib are preferred for untreated disease since the availability of alectinib. Brigatinib has been approved for previously treated disease only after crizotinib. If alectinib's treatment effect wanes the only current option is chemotherapy. ALK TKI treatments

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Evidence Report for Investigating symptoms of lung cancer: a guide for all health professionals

, which can hinder early diagnosis and treatment. 4, 5 Lung cancer presentations can also be complex, due to co-morbidities or plausible alternative diagnoses. 6 Lung cancer symptoms can present in a similar manner to other conditions such as chronic obstructive pulmonary disease (COPD), chronic heart failure and coronary heart disease. 7 Therefore, it is important to increase awareness of lung cancer symptoms and risk factors, and to provide all health professionals with the most recent evidence (...) with symptoms or signs consistent with lung cancer. The Guide does not provide advice on the following: • adults with mesothelioma • adults with lung metastases arising from primary cancer originating outside the lung • children (younger than 18 years) with lung cancer • adults with rare lung tumours • adults with benign lung tumours, and • adults being screened for lung cancer. For more information on the potential role of screening for asymptomatic patients, visit Cancer Australia’s lung cancer screening

2020 Cancer Australia

9. Investigating symptoms of lung cancer: a guide for all health professionals

The association of lung cancer with smoking can lead to lung cancer patients feeling stigmatised, contributing to delays in help-seeking for symptoms 4,5 and psychological distress. 6 Risk factors for lung cancer Lifestyle factors - current or former tobacco smoking Environmental or occupational factors - passive smoking - occupational exposures e.g. radon, asbestos, diesel exhaust, silica - air pollution Personal factors - increasing age - family history of lung cancer - chronic lung disease e.g. chronic (...) obstructive pulmonary disease (COPD), pulmonary fibrosis - personal history of cancer e.g. lung cancer, head and neck cancer, bladder cancer Symptoms and signs of lung cancer Symptoms can present in a similar manner to other conditions such as COPD, chronic heart failure and coronary heart disease. 7 Please refer to the flow chart overleaf for symptoms and signs of lung cancer, recommended investigations and referrals, and timeframes for referral. 80 90 100 70 60 50 40 30 20 10 Stage at diagnosis and 5

2020 Cancer Australia

10. Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer

and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials April 2019, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to May 16, 2019 Search Strategy: # Searches 1 exp lung neoplasms/ or exp lung cancer/ 2 (((lung or thorax or thoracic or pulmonary) adj3 (cancer$ or neoplasm$ or carcinom$ or malignan$ or tumo?r$ or adenocarcinoma$)) or NSCLC).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, ui, sy, sh, tx, ct] 3 1 or 2 4 exp (...) , P.M. Ellis, R. Goffin, W. Hanna, D. Maziak, A. Swaminath, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: April 27, 2020 This document describes the OH (CCO)-Lung Cancer Disease Site Group endorsement of the recommendations for the treatment of patients with clinical stage III N2 non-small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available at www.nice.org.uk/guidance/ng122. The recommendations were also endorsed

2020 Cancer Care Ontario

11. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report

screening, defer surveillance imaging of lung nodules, and minimize nonurgent interventions during the evaluation of lung nodules and stage I non-small cell lung cancer. INTERPRETATION: There was consensus that during the COVID-19 pandemic, it is appro- priatetodeferenrollmentinlungcancerscreeningandmodifytheevaluationoflungnodules ABBREVIATIONS: CDC = Centers for Disease Control and Prevention; COVID-19 = coronavirus disease 19; Lung-RADS = Lung CT Screening Reporting and Data System; pCA = probability (...) : consensus statement; COVID-19; lung cancer screening; lung nodule In some parts of the world, the coronavirus disease 2019 (COVID-19) pandemic has stressed the health- care systems close to or even past their breaking point. Rightfully, much of the attention to date has focused on the immediate needs of patients suffering from the disease, particularly those who are critically ill. The strain on health-care systems and the need to control the virus using containment (testing and isolating cases

2020 American College of Chest Physicians

12. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study

of China. 15 Cliniche Humanitas Gavazzeni, Bergamo, Italy. 16 Merck & Co, Kenilworth, NJ. 17 The Netherlands Cancer Institute, Amsterdam, the Netherlands. PMID: 32078391 DOI: Item in Clipboard Full-text links Cite Abstract Purpose: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report (...) Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates

13. Association between polymorphisms of epidermal growth factor 61 and susceptibility of lung cancer: A meta-analysis. (Full text)

Association between polymorphisms of epidermal growth factor 61 and susceptibility of lung cancer: A meta-analysis. To explore the association between epidermal growth factor (EGF) 61A/G polymorphism and lung cancer.All eligible case-control studies published up to August, 2019 were identified by searching PubMed, The excerpta medica database, China Academic Journals Full-text Database, China Biology Medicine, China National Knowledge Infrastructure, China Science and Technology Journal (...) Database, and Wanfang databases. Two researchers independently identified the literature, extracted data, and evaluated quality according to inclusion and exclusion criteria. Meta-analysis was performed by Stata 15.0.A total of 6 studies is included, including 1487 cases and 2044 control subjects. Compared with allele A, allele G was considered to have no association with the risk of lung cancer, odds ratio = 1.07 (95% confidence interval: 0.98-1.15). GG recessive genotype, GG + GA dominant genotype

2020 Medicine PubMed abstract

14. Clinicopathological and prognostic significance of thyroid transcription factor-1 expression in small cell lung cancer: A systemic review and meta-analysis. (Abstract)

Clinicopathological and prognostic significance of thyroid transcription factor-1 expression in small cell lung cancer: A systemic review and meta-analysis. To explore the association of thyroid transcription factor-1 (TTF-1) expression status with clinicopathological characteristics and survival of patients with small cell lung cancer (SCLC).A comprehensive literature search was conducted to identify potentially relevant studies in several electronic databases, including EMBASE, PubMed, Web

2020 Pathology, research and practice

15. Is carrot consumption associated with a decreased risk of lung cancer? A meta-analysis of observational studies. (Full text)

cancer. The pooled OR of eighteen studies for lung cancer was 0·58 (95 % CI 0·45, 0·74) by comparing the highest category with the lowest category of carrot consumption. Based on subgroup analyses for the types of lung cancer, we pooled that squamous cell carcinoma (OR 0·52, 95 % CI 0·19, 1·45), small-cell carcinoma (OR 0·43, 95 % CI 0·12, 1·59), adenocarcinoma (OR 0·34, 95 % CI 0·15, 0·79), large-cell carcinoma (OR 0·40, 95 % CI 0·10, 1·57), squamous and small-cell carcinoma (OR 0·85, 95 % CI 0·45 (...) , 1·62), adenocarcinoma and large-cell carcinoma (OR 0·20, 95 % CI 0·02, 1·70) and mixed types (OR 0·61, 95 % CI 0·46, 0·81). Exclusion of any single study did not materially alter the pooled OR. Integrated epidemiological evidence from observational studies supported the hypothesis that carrot consumption may decrease the risk of lung cancer, especially for adenocarcinoma.

2020 The British journal of nutrition PubMed abstract

16. The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced Lung Cancer: A Meta-Analysis of 80 Randomized Controlled Trials. (Abstract)

The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced Lung Cancer: A Meta-Analysis of 80 Randomized Controlled Trials. Chemotherapy-induced hepatorenal toxicity often decreases tolerance for further therapies and results in poor quality of life and prognosis for patients with lung cancer. In this meta-analysis, all related studies were systematically re-evaluated to determine whether Aidi injection relieves hepatorenal toxicity and improves tumor (...) days per cycle, and 2 to 3 cycles of Aidi injection with chemotherapy resulted in a low incidence of hepatorenal toxicity. All of the results were robust, and their quality was moderate.The moderate evidence indicates that Aidi injection with chemotherapy may improve tumor response and result in a low incidence of hepatorenal toxicity in patients with lung cancer. Aidi injection may relieve hepatorenal toxicity and exhibit an important protective effect against chemotherapy-induced hepatorenal

2020 Clinical therapeutics

17. Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis. (Abstract)

Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis. To perform a systematic review and meta-analysis evaluating usefulness of high-risk CT features (HRFs) on follow-up CT in detecting local recurrence after stereotactic body radiation therapy (SBRT) in lung cancer patients.Pubmed and EMBASE were searched up to January 11th, 2019. We included studies that differentiated local recurrence from post (...) -SBRT changes after SBRT on follow-up CT in lung cancer patients. Methodological quality was assessed using QUADAS-2. The association between HRFs and local recurrence were pooled in the form of odds ratio (OR) using the random effects model. Heterogeneity was examined by the Inconsistency index (I2).Eight studies were included, consisting of 356 lung cancer patients. The overall prevalence of patients with local recurrence was 18.8 % (67/356). Compared with post-SBRT changes, local recurrence after

2020 European journal of radiology

18. Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer. (Full text)

Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer. In recent years, many studies on the relationship between the expression of microRNA-126(miR-126) and the diagnostic and prognostic value of non-small cell lung cancer (NSCLC)have been made, but the results were still controversial.The aim is to explore the expression of miR-126 and the diagnosis and prognosis value of NSCLC, and to provide relevant evidence for clinical diagnosis and treatment

2020 Bioscience reports PubMed abstract

19. Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. (Full text)

Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. This network meta-analysis (NMA), based on one phase II and nine phase III studies, involving 6,124 patients with metastatic NSCLC, indirectly compares Atezolizumab + Bevacizumab + chemotherapy (ABC), Atezolizumab + chemotherapy (AC), Pembrolizumab + chemotherapy (PC), Pembrolizumab alone, Bevacizumab + chemotherapy (BC

2020 Oncoimmunology PubMed abstract

20. Effects of Breathing Exercises on Patients With Lung Cancer. (Full text)

Effects of Breathing Exercises on Patients With Lung Cancer. To evaluate the effects of breathing exercises on dyspnea, six-minute walk distance (6MWD), anxiety, and depression in patients with lung cancer.A systematic literature search of the Cochrane Library, Web of Science, Embase®, PubMed®, Weipu, Wanfang, and Chinese National Knowledge Infrastructure databases was performed for publications dated prior to April 6, 2018.The meta-analysis was performed using Review Manager and Stata.15

2020 Oncology nursing forum PubMed abstract